Result for
Tag: candidate
September 30, 2020
Risk of COVID-19-Related Death among Patients with Chronic Obstructive Pulmonary Disease or Asthma Prescribed Inhaled Corticosteroids: An Observational Cohort Study Using the OpenSAFELY Platform
In a large cohort of people with chronic obstructive pulmonary disease (COPD) in the UK (n=148,557), and asthma (818,490), Schultze et al. found an increased risk of COVID-19 related death associated with use of inhaled corticosteroids, compared to other commonly-used medications. The authors note that the observed increased risks could be attributed to unmeasured confounding…
Reliability of Serological Tests for COVID-19: Comparison of Three Immunochromatography Test Kits for SARS-CoV-2 Antibodies
Three commercially available serological test kits using immunochromatography (Hangzhou AllTest, SD BIOSENSOR, and Vazyme) were evaluated using identical sample sets consisting of 99 serum samples from SARS-CoV-2 positive patients and 100 serum samples from healthy volunteers in 2017. All test kits achieved >97% specificity for IgM and IgG and >97% sensitivity to IgG at 13…
The Role of Anti-Hypertensive Treatment, Comorbidities and Early Introduction of LMWH in the Setting of COVID-19: A Retrospective, Observational Study in Northern Italy
Chronic treatment with the antihypertensive medications angiotensin converting enzyme inhibitors (ACE-I) and early treatment with low-molecular-weight heparin (LMWH) were both associated with lower in-hospital mortality in a cohort of patients hospitalized with COVID-19 in Italy (n=575), after adjusting for age. Angiotensin receptor blockers, which are also antihypertensive agents acting on the same physiological pathway, were…
Comparative Study of Four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) Platforms Demonstrates That ID NOW Performance Is Impaired Substantially by Patient and Specimen Type
The nucleic acid amplification test (NAAT) platform Abbott ID NOW performed significantly worse than similar tests (Abbott m2000, DiaSorine Simplexa, and Cepheid Xpert) in detecting SARS-CoV-2 RNA in a comparative study. All four tests were used in parallel on nasopharyngeal and nasal samples from 88 emergency department and hospital-admitted patients. In particular, the ID NOW…
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
Daily administration of hydroxychloroquine to hospital-based healthcare workers as pre-exposure prophylaxis against SARS-CoV-2 infection did not change infection risk between participants receiving hydroxychloroquine vs placebo (6.3% vs 6.6%, p>0.99) in this randomized, double-blind, placebo-controlled trial (n=132). The trial was terminated early due to futility and may have been underpowered to detect clinically important differences. Abella…
August 20, 2020
Mass Testing for SARS-CoV-2 in 16 Prisons and Jails — Six Jurisdictions, United States
The mass testing conducted among incarcerated or detained persons across 16 prisons and jails from 6 US jurisdictions (April 11-May 20, 2020) identified a total of 8,239 persons with SARS-CoV-2 among 16,392 individuals tested, representing a median 12-fold increase over the number of cases in each facility by earlier symptom-based testing. Prevalence in jails and…
Previous page